Discovery cohort | Validation cohort | |||||
HR | 95% CI | P values | HR | 95% CI | P values | |
Primary analysis: adjusted for age, diuretic treatment and atrial fibrillation | ||||||
HDL-4-Apo A-2 | 0.48 | 0.33 to 0.7 | 1.35×10–4 | 0.6 | 0.43 to 0.84 | 2.67×10–3 |
HDL-4-Apo A-1 | 0.51 | 0.35 to 0.73 | 2.41×10–4 | 0.62 | 0.46 to 0.85 | 3.03×10–3 |
HDL-4-phospholipids | 0.54 | 0.38 to 0.76 | 3.75×10–4 | 0.61 | 0.44 to 0.84 | 2.33×10–3 |
Secondary analysis: adjusted for 6MWD and NT-proBNP | ||||||
HDL-4-Apo A-2 | 0.55 | 0.36 to 0.84 | 6.03×10–3 | 0.61 | 0.43 to 0.86 | 5.18×10–3 |
HDL-4-Apo A-1 | 0.63 | 0.42 to 0.96 | 3.29×10–2 | 0.65 | 0.47 to 0.92 | 1.38×10–2 |
HDL-4-phospholipids | 0.63 | 0.42 to 0.94 | 2.38×10–2 | 0.64 | 0.46 to 0.89 | 7.91×10–3 |
Secondary analysis: adjusted for HDL cholesterol, LDL cholesterol and CRP | ||||||
HDL-4-Apo A-2 | 0.57 | 0.39 to 0.84 | 4.53×10–3 | 0.54 | 0.34 to 0.86 | 9.32×10–3 |
HDL-4-Apo A-1 | 0.60 | 0.40 to 0.90 | 1.41×10–2 | 0.53 | 0.33 to 0.85 | 8.28×10–3 |
HDL-4-phospholipids | 0.61 | 0.41 to 0.91 | 1.53×10–2 | 0.51 | 0.32 to 0.82 | 5.03×10–3 |
↵Apo, apolipoprotein; CI, confidence interval; CRP, C reactive protein; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; 6MWD, 6 min walk distance; NT-proBNP, N-terminal pro-brain natriuretic peptide.